Barclays PLC Purchases 30,902 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)

Barclays PLC lifted its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 317.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,644 shares of the company’s stock after purchasing an additional 30,902 shares during the quarter. Barclays PLC owned 0.08% of scPharmaceuticals worth $186,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SCPH. Geode Capital Management LLC lifted its position in scPharmaceuticals by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 643,342 shares of the company’s stock valued at $2,934,000 after acquiring an additional 61,582 shares in the last quarter. XTX Topco Ltd bought a new stake in scPharmaceuticals in the 3rd quarter valued at $124,000. State Street Corp lifted its position in scPharmaceuticals by 5.2% in the 3rd quarter. State Street Corp now owns 682,135 shares of the company’s stock valued at $3,111,000 after acquiring an additional 33,879 shares in the last quarter. Captrust Financial Advisors lifted its position in scPharmaceuticals by 32.2% in the 3rd quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after acquiring an additional 4,513 shares in the last quarter. Finally, Walleye Capital LLC lifted its position in scPharmaceuticals by 27.0% in the 3rd quarter. Walleye Capital LLC now owns 475,555 shares of the company’s stock valued at $2,169,000 after acquiring an additional 101,148 shares in the last quarter. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Trading Down 0.9 %

scPharmaceuticals stock opened at $3.21 on Thursday. The firm has a 50-day moving average of $3.44 and a 200-day moving average of $4.23. scPharmaceuticals Inc. has a one year low of $3.08 and a one year high of $6.54. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The company has a market cap of $160.63 million, a price-to-earnings ratio of -1.69 and a beta of 0.11.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SCPH shares. Craig Hallum cut their price objective on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, November 14th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.